OTUD1 promotes pathological cardiac remodeling and heart failure by targeting STAT3 in cardiomyocytes

Rationale: Understanding the molecular mechanisms of deleterious cardiac remodeling is important for the development of treatments for heart failure. Recent studies have highlighted a role of deubiquitinating enzymes in cardiac pathophysiology. In the present study, we screened for alteration of deubiquitinating enzymes in experimental models of cardiac remodeling, which indicated a potential role of OTU Domain-Containing Protein 1 (OTUD1). Methods: Wide-type or OTUD1 knockout mice with chronic angiotensin II infusion and transverse aortic constriction (TAC) were utilized to develop cardiac remodeling and heart failure. We also overexpressed OTUD1 in mouse heart with AAV9 vector to validate the function of OTUD1. LC-MS/MS analysis combined with Co-IP was used to identify the interacting proteins and substrates of OTUD1. Results: We found that OTUD1 is elevated in mouse heart tissues following chronic angiotensin II administration. OTUD1 knockout mice were significantly protected against angiotensin II-induced cardiac dysfunction, hypertrophy, fibrosis and inflammatory response. Similar results were obtained in the TAC model. Mechanistically, OTUD1 bounds to the SH2 domain of STAT3 and causes deubiquitination of STAT3. Cysteine at position 320 of OTUD1 exerts K63 deubiquitination to promote STAT3 phosphorylation and nuclear translocation, thereby increasing STAT3 activity to induce inflammatory responses, fibrosis, and hypertrophy in cardiomyocytes. Finally, OTUD1 overexpression by AAV9 vector increases Ang II-induced cardiac remodeling in mice and OTUD1-regulated responses can be inhibited by blocking STAT3. Conclusion: Cardiomyocyte OTUD1 promotes pathological cardiac remodeling and dysfunction by deubiquitinating STAT3. These studies have highlighted a novel role of OTUD1 in hypertensive heart failure and identified STAT3 as a target of OTUD1 in mediating these actions.

[1]  D. Longley,et al.  The role of Ubiquitination in Apoptosis and Necroptosis , 2021, Cell Death & Differentiation.

[2]  Lingqiang Zhang,et al.  The deubiquitinase OTUD1 inhibits colonic inflammation by suppressing RIPK1-mediated NF-κB signaling , 2021, Cellular & Molecular Immunology.

[3]  M. Vázquez-Carrera,et al.  Crosstalk between the renin-angiotensin system and the endoplasmic reticulum stress in the cardiovascular system: Lessons learned so far. , 2021, Life sciences.

[4]  Zhihua Liu,et al.  OTUD1 Activates Caspase‐Independent and Caspase‐Dependent Apoptosis by Promoting AIF Nuclear Translocation and MCL1 Degradation , 2021, Advanced science.

[5]  I. Wertz,et al.  Ubiquitination in the regulation of inflammatory cell death and cancer , 2021, Cell Death & Differentiation.

[6]  F. You,et al.  The deubiquitinase OTUD1 enhances iron transport and potentiates host antitumor immunity , 2021, EMBO reports.

[7]  Yibin Kang,et al.  Deubiquitinase USP20 promotes breast cancer metastasis by stabilizing SNAI2 , 2020, Genes & development.

[8]  Guodong Wu,et al.  Identification of Target Genes in Hypertension and Left Ventricular Remodeling , 2020, Medicine.

[9]  S. Dikalov,et al.  Response by Dikalova and Dikalov to Letter Regarding Article, "Mitochondrial Deacetylase Sirt3 Reduces Vascular Dysfunction and Hypertension While Sirt3 Depletion in Essential Hypertension Is Linked to Vascular Inflammation and Oxidative Stress". , 2020, Circulation research.

[10]  Xiang Hu,et al.  Celastrol Attenuates Angiotensin II–Induced Cardiac Remodeling by Targeting STAT3 , 2020, Circulation research.

[11]  F. You,et al.  OTUD1 Negatively Regulates Type I IFN Induction by Disrupting Noncanonical Ubiquitination of IRF3 , 2020, The Journal of Immunology.

[12]  J. Auwerx,et al.  Mitochondrial Deacetylase Sirt3 Reduces Vascular Dysfunction and Hypertension While Sirt3 Depletion in Essential Hypertension Is Linked to Vascular Inflammation and Oxidative Stress , 2019, Circulation research.

[13]  R. Touyz,et al.  Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure , 2019, Pharmacological Reviews.

[14]  M. Sorrentino.  The Evolution from Hypertension to Heart Failure. , 2019, Heart failure clinics.

[15]  Weijian Huang,et al.  Emodin alleviates myocardial ischemia/reperfusion injury by inhibiting gasdermin D-mediated pyroptosis in cardiomyocytes , 2019, Drug design, development and therapy.

[16]  D. Duong,et al.  Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation , 2019, Nature Communications.

[17]  X. Zuo,et al.  Ubiquitination in Scleroderma Fibrosis and Its Treatment , 2018, Front. Immunol..

[18]  Chen Ding,et al.  Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7 , 2017, Nature Communications.

[19]  Jun Zhu,et al.  Tumor necrosis factor receptor-associated factor 6 (TRAF6) mediates ubiquitination-dependent STAT3 activation upon Salmonella Typhimurium infection , 2017 .

[20]  S. Rossi,et al.  MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression. , 2016, The Journal of clinical investigation.

[21]  Jiayuh Lin,et al.  STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells , 2016, International journal of oncology.

[22]  B. He,et al.  Ubiquitin-Specific Protease 4 Is an Endogenous Negative Regulator of Pathological Cardiac Hypertrophy , 2016, Hypertension.

[23]  Y. Kee,et al.  Role of Deubiquitinating Enzymes in DNA Repair , 2015, Molecular and Cellular Biology.

[24]  H. Shu,et al.  Induction of USP25 by viral infection promotes innate antiviral responses by mediating the stabilization of TRAF3 and TRAF6 , 2015, Proceedings of the National Academy of Sciences.

[25]  J. S. Janicki,et al.  Deubiquitinating enzyme CYLD mediates pressure overload-induced cardiac maladaptive remodeling and dysfunction via downregulating Nrf2. , 2015, Journal of molecular and cellular cardiology.

[26]  C. Robson,et al.  Deubiquitinating enzymes as oncotargets , 2015, Oncotarget.

[27]  F. He,et al.  The Ubiquitin Ligase TRAF6 Negatively Regulates the JAK-STAT Signaling Pathway by Binding to STAT3 and Mediating Its Ubiquitination , 2012, PloS one.

[28]  Y. Ihara,et al.  The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease. , 2012, Cold Spring Harbor Perspectives in Medicine.

[29]  J. Coulson,et al.  Cellular functions of the DUBs , 2012, Journal of Cell Science.

[30]  Rekha Singh.  Jak2-Independent Activation of Stat3 by Intracellular Angiotensin II in Human Mesangial Cells , 2011, Journal of signal transduction.

[31]  F. Colland,et al.  Ubiquitin-specific proteases as cancer drug targets. , 2011, Future oncology.

[32]  H. Drexler,et al.  The myocardial JAK/STAT pathway: from protection to failure. , 2008, Pharmacology & therapeutics.

[33]  G. Booz,et al.  Can the Protective Actions of JAK-STAT in the Heart be Exploited Therapeutically? Parsing the Regulation of Interleukin-6-Type Cytokine Signaling , 2007, Journal of cardiovascular pharmacology.

[34]  De-Pei Liu,et al.  Targeted Cardiac Overexpression of A20 Improves Left Ventricular Performance and Reduces Compensatory Hypertrophy After Myocardial Infarction , 2007, Circulation.

[35]  Bianca Sperl,et al.  Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. , 2006, Chemistry & biology.

[36]  C. Patterson,et al.  Into the heart: the emerging role of the ubiquitin-proteasome system. , 2006, Journal of molecular and cellular cardiology.

[37]  N. Reich,et al.  Tracking STAT nuclear traffic , 2006, Nature Reviews Immunology.

[38]  A. Goldberg,et al.  Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. , 2006, Journal of the American Society of Nephrology : JASN.

[39]  René Bernards,et al.  A Genomic and Functional Inventory of Deubiquitinating Enzymes , 2005, Cell.

[40]  H. Drexler,et al.  Many good reasons to have STAT3 in the heart. , 2005, Pharmacology & therapeutics.

[41]  Kevin M. McBride,et al.  STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Litterst,et al.  The role of STATs in inflammation and inflammatory diseases. , 2004, Current pharmaceutical design.

[43]  Y. Ahn,et al.  A20 Is Dynamically Regulated in the Heart and Inhibits the Hypertrophic Response , 2003, Circulation.

[44]  J. Díez,et al.  Cardiomyocyte Apoptotic Cell Death in Arterial Hypertension: Mechanisms and Potential Management , 2001, Hypertension.

[45]  J. Ross,et al.  Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways. , 2001, The Journal of clinical investigation.

[46]  M. Okabe,et al.  Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[47]  B. Jensen,et al.  The nuclear receptor RORα protects against angiotensin II-induced cardiac hypertrophy and heart failure. , 2019, American journal of physiology. Heart and circulatory physiology.